Novartis expands Orionis partnership in $1.4B deal to advance AI‑driven molecular glue therapeutics across oncology, immunology, and neuroscience.
Written By: Samiksha Jadhav, BPharm
Reviewed By: Pharmacally Editorial Team
Novartis has expanded its partnership with Orionis Biosciences through a multi-year agreement focused on discovering molecular glue therapeutics across multiple disease areas. The collaboration broadens an existing alliance and combines Novartis’ drug development expertise with Orionis’ proprietary Allo-Glue™ platform and AI-powered discovery technologies.
Under the agreement, Orionis will receive $40 million upfront and is eligible for up to $1.4 billion in research, development, and commercial milestone payments, in addition to tiered royalties on future product sales.
Advancing Molecular Glue Discovery
The collaboration will use Orionis’ Allo-Glue platform and AI-driven discovery engine to accelerate target identification, ligase profiling, and molecular glue optimization.
Molecular glues are small molecules that induce protein-protein interactions, enabling the degradation, stabilization, or modulation of disease-related proteins that may be difficult to address with conventional drug approaches. The technology has emerged as a promising therapeutic modality across oncology, immunology, neuroscience, and other disease areas.
Orionis has integrated artificial intelligence and robotic automation into its discovery workflow, helping researchers identify productive target-ligase pairs and optimize molecular glue candidates more efficiently.
Scientific and Strategic Perspectives
Orionis Chief Executive Officer Niko Kley said the expanded agreement reflects confidence in the company’s molecular glue platform and validates its progress toward a more systematic and scalable approach to glue discovery.
Riccardo Sabatini, Orionis’ Chief Data Scientist, highlighted recent advances in AI and automation that have accelerated key stages of molecular glue research, from target prioritization to candidate optimization.
John Tallarico, Head of Discovery Sciences at Novartis, said the collaboration provides an opportunity to uncover new molecular glue mechanisms and broaden the range of biologically relevant targets that can be pursued therapeutically.
Implications for Future Therapeutics
The expanded alliance strengthens Novartis’ position in the rapidly evolving field of induced-proximity therapeutics and supports multiple discovery programs across a broad range of disease areas.
As investment in molecular glue technologies continues to grow, the partnership underscores increasing industry interest in new drug discovery approaches that combine induced-proximity biology, artificial intelligence, and automation to generate next-generation therapeutic candidates.
Reference
About the Writer
Samiksha Vikram Jadhav (LinkedIn) is a B. Pharm graduate with a strong academic foundation in pharmaceutical sciences, pharmacology, and drug development. She specializes in pharma market research, with a focused interest in mergers and acquisitions, strategic partnerships, and global pharma and biotech deals. Her work centers on analyzing industry transactions, market positioning, and business strategies, translating complex developments into clear, accurate, and insightful scientific and commercial reporting.